{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T10:15:37Z","timestamp":1768644937992,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T00:00:00Z","timestamp":1468454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004756","name":"Emil Aaltonen Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004756","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005878","name":"Terveyden Tutkimuksen Toimikunta","doi-asserted-by":"publisher","award":["256837"],"award-info":[{"award-number":["256837"]}],"id":[{"id":"10.13039\/501100005878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007083","name":"Orion Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007083","id-type":"DOI","asserted-by":"crossref"}]},{"name":"P\u00e4ivikki and Sakari Sohlberg`s Foundation"},{"name":"University of Eastern Finland Postdoctoral program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s11064-016-1996-8","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T06:16:23Z","timestamp":1468476983000},"page":"2797-2809","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1403-299X","authenticated-orcid":false,"given":"Mikko","family":"Gynther","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauri","family":"Peura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Vernerov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jukka","family":"Lepp\u00e4nen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jussi","family":"K\u00e4rkk\u00e4inen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Lehtonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarkko","family":"Rautio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristiina M.","family":"Huttunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,14]]},"reference":[{"key":"1996_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00666.x","volume":"184","author":"A Aldenkamp","year":"2006","unstructured":"Aldenkamp A, Vigevano F, Arzimanoglou A, Covanis A (2006) Role of valproate across the ages. Treatment of epilepsy in children. Acta Neurol Scand Suppl 184:1\u201313","journal-title":"Acta Neurol Scand Suppl"},{"key":"1996_CR2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0404.2006.00667.x","volume":"184","author":"E Ben-Menachem","year":"2006","unstructured":"Ben-Menachem E, Schmitz B, Tomson T, Vajda F (2006) Role of valproate across the ages. Treatment of epilepsy in adults. Acta Neurol Scand Suppl 184:14\u201327","journal-title":"Acta Neurol Scand Suppl"},{"key":"1996_CR3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1600-0404.2006.00668.x","volume":"184","author":"E Perucca","year":"2006","unstructured":"Perucca E, Aldenkamp A, Tallis R, Kramer G (2006) Role of valproate across the ages. Treatment of epilepsy in the elderly. Acta Neurol Scand Suppl 184:28\u201337","journal-title":"Acta Neurol Scand Suppl"},{"issue":"7","key":"1996_CR4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1528-1167.2012.03712.x","volume":"53","author":"M Bialer","year":"2012","unstructured":"Bialer M (2012) Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia 53(Suppl 7):26\u201333","journal-title":"Epilepsia"},{"key":"1996_CR5","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1042\/BST0371126","volume":"37","author":"N Terbach","year":"2009","unstructured":"Terbach N, Williams RS (2009) Structure\u2013function studies for the panacea, valproic acid. Biochem Soc Trans 37:1126\u20131132","journal-title":"Biochem Soc Trans"},{"key":"1996_CR6","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/S0024-3205(96)00687-X","volume":"60","author":"JP Bolanos","year":"1997","unstructured":"Bolanos JP, Medina JM (1997) Effect of valproate on the metabolism of the central nervous system. Life Sci 60:1933\u20131942","journal-title":"Life Sci"},{"key":"1996_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2013.08.016","volume":"107","author":"V Belcastro","year":"2013","unstructured":"Belcastro V, D\u2019Egidio C, Striano P, Verrotti A (2013) Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res 107:1\u20138","journal-title":"Epilepsy Res"},{"key":"1996_CR8","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","volume":"46","author":"RM Nanau","year":"2013","unstructured":"Nanau RM, Neuman MG (2013) Adverse drug reactions induced by valproic acid. Clin Biochem 46:1323\u20131338","journal-title":"Clin Biochem"},{"key":"1996_CR9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","volume":"31","author":"MF Silva","year":"2008","unstructured":"Silva MF, Aires CC, Luis PB, Ruiter JP, L IJ, Duran M, Wanders RJ, Tavares de Almeida I (2008) Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 31:205\u2013216","journal-title":"J Inherit Metab Dis"},{"key":"1996_CR10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/toxsci\/kfl096","volume":"94","author":"TK Kiang","year":"2006","unstructured":"Kiang TK, Ho PC, Anari, Tong MR, Abbott V, Chang FS, TK (2006) Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1\/*1 genotype. Toxicol Sci 94:261\u2013271","journal-title":"Toxicol Sci"},{"key":"1996_CR11","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1517\/17425255.2014.956081","volume":"10","author":"D Italiano","year":"2014","unstructured":"Italiano D, Spina E, de Leon J (2014) Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opin Drug Metab Toxicol 10:1457\u20131489","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1996_CR12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157015910792246254","volume":"8","author":"SI Johannessen","year":"2010","unstructured":"Johannessen SI, Landmark CJ (2010) Antiepileptic drug interactions-principles and clinical implications. Curr Neuropharmacol 8:254\u2013267","journal-title":"Curr Neuropharmacol"},{"key":"1996_CR13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/clinchem\/31.1.60","volume":"31","author":"J Barre","year":"1985","unstructured":"Barre J, Chamouard JM, Houin G, Tillement JP (1985) Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin Chem 31:60\u201364","journal-title":"Clin Chem"},{"key":"1996_CR14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3109\/00498254.2014.978413","volume":"45","author":"AM Svennebring","year":"2015","unstructured":"Svennebring AM (2015) Investigation of the prerequisites for the optimization of specific plasma protein binding as a strategy for the reduction of first-pass hepatic metabolism. Xenobiotica 45:286\u2013301","journal-title":"Xenobiotica"},{"key":"1996_CR15","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1471-4159.1985.tb08793.x","volume":"44","author":"EM Cornford","year":"1985","unstructured":"Cornford EM, Diep CP, Pardridge WM (1985) Blood\u2013brain barrier transport of valproic acid. J Neurochem 44:1541\u20131550","journal-title":"J Neurochem"},{"key":"1996_CR16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1006\/bbrc.1995.2312","volume":"214","author":"I Tamai","year":"1995","unstructured":"Tamai I, Takanaga H, Maeda H, Sai Y, Ogihara T, Higashida H, Tsuji A (1995) Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids. Biochem Biophys Res Commun 214:482\u2013489","journal-title":"Biochem Biophys Res Commun"},{"key":"1996_CR17","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1023\/A:1013310210710","volume":"18","author":"K Hosoya","year":"2001","unstructured":"Hosoya K, Kondo T, Tomi M, Takanaga H, Ohtsuki S, Terasaki T (2001) MCT1-mediated transport of l-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina. Pharm Res 18:1669\u20131676","journal-title":"Pharm Res"},{"key":"1996_CR18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1248\/bpb1978.13.158","volume":"13","author":"YS Kang","year":"1990","unstructured":"Kang YS, Terasaki T, Tsuji A (1990) Acidic drug transport in vivo through the blood\u2013brain barrier. A role of the transport carrier for monocarboxylic acids. J Pharmacobiodyn 13:158\u2013163","journal-title":"J Pharmacobiodyn"},{"key":"1996_CR19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.2042-7158.1991.tb06660.x","volume":"43","author":"T Terasaki","year":"1991","unstructured":"Terasaki T, Kang YS, Ohnishi T, Tsuji A (1991) In-vitro evidence for carrier-mediated uptake of acidic drugs by isolated bovine brain capillaries. J Pharm Pharmacol 43:172\u2013176","journal-title":"J Pharm Pharmacol"},{"key":"1996_CR20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0022-3565(25)12397-5","volume":"276","author":"KDK Adkison","year":"1996","unstructured":"Adkison, KDK, Shen DD (1996) Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter. J Pharmacol Exp Ther 276:1189\u20131200","journal-title":"J Pharmacol Exp Ther"},{"key":"1996_CR21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1006\/mvre.2001.2378","volume":"63","author":"A Kakee","year":"2002","unstructured":"Kakee A, Takanaga H, Hosoya K, Sugiyama Y, Terasaki T (2002) In vivo evidence for brain-to-blood efflux transport of valproic acid across the blood\u2013brain barrier. Microvasc Res 63:233\u2013238","journal-title":"Microvasc Res"},{"key":"1996_CR22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/jpet.106.102491","volume":"320","author":"S Baltes","year":"2007","unstructured":"Baltes S, Fedrowitz M, Tortos CL, Potschka H, Loscher W (2007) Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 320:331\u2013343","journal-title":"J Pharmacol Exp Ther"},{"key":"1996_CR23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0006-8993(00)02893-6","volume":"884","author":"JL Scism","year":"2000","unstructured":"Scism JL, Powers KM, Artru AA, Lewis L, Shen DD (2000) Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. Brain Res 884:77\u201386","journal-title":"Brain Res"},{"key":"1996_CR24","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1021\/mp2001878","volume":"8","author":"L Peura","year":"2011","unstructured":"Peura L, Malmioja K, Laine K, Leppanen J, Gynther M, Isotalo A, Rautio J (2011) Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery. Mol Pharm 8:1857\u20131866","journal-title":"Mol Pharm"},{"key":"1996_CR25","doi-asserted-by":"crossref","first-page":"12079","DOI":"10.1073\/pnas.96.21.12079","volume":"96","author":"RJ Boado","year":"1999","unstructured":"Boado RJ, Li JY, Nagaya, Zhang M, Pardridge C, WM (1999) Selective expression of the large neutral amino acid transporter at the blood\u2013brain barrier. Proc Natl Acad Sci USA 96:12079\u201312084","journal-title":"Proc Natl Acad Sci USA"},{"key":"1996_CR26","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1124\/mol.61.4.729","volume":"61","author":"H Uchino","year":"2002","unstructured":"Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, Endou H (2002) Transport of amino acid-related compounds mediated by l-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 61:729\u2013737","journal-title":"Mol Pharmacol"},{"key":"1996_CR27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/1389200033489253","volume":"4","author":"K Beaumont","year":"2003","unstructured":"Beaumont K, Webster R, Gardner I, Dack K (2003) Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab 4:461\u2013485","journal-title":"Curr Drug Metab"},{"key":"1996_CR28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/molecules13020412","volume":"13","author":"M Hosokawa","year":"2008","unstructured":"Hosokawa M (2008) Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 13:412\u2013431","journal-title":"Molecules"},{"key":"1996_CR29","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/jps.20542","volume":"95","author":"BM Liederer","year":"2006","unstructured":"Liederer BM, Borchardt RT (2006) Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 95:1177\u20131195","journal-title":"J Pharm Sci"},{"key":"1996_CR30","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1021\/jm901181h","volume":"52","author":"DM Bender","year":"2009","unstructured":"Bender DM, Bao J, Dantzig AH, Diseroad WD, Law KL, Magnus NA, Peterson JA, Perkins EJ, Pu YJ, Reutzel-Edens SM, Remick DM, Starling JJ, Stephenson GA, Vaid RK, Zhang D, McCarthy JR (2009) Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J Med Chem 52:6958\u20136961","journal-title":"J Med Chem"},{"key":"1996_CR31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/1061186042000223653","volume":"12","author":"T Gong","year":"2004","unstructured":"Gong T, Huang Y, Zhang ZR, Li LL (2004) Synthesis and characterization of 9-[P-(N, N-dipropyl sulfamide)] benzoylamino-1,2,3,4\u20134\u00a0H-acridine\u2013a potential prodrug for the CNS delivery of tacrine. J Drug Target 12:177\u2013182","journal-title":"J Drug Target"},{"key":"1996_CR32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijpharm.2010.08.019","volume":"399","author":"M Gynther","year":"2010","unstructured":"Gynther M, Jalkanen A, Lehtonen M, Forsberg M, Laine K, Ropponen J, Leppanen J, Knuuti J, Rautio J (2010) Brain uptake of ketoprofen\u2013lysine prodrug in rats. Int J Pharm 399:121\u2013128","journal-title":"Int J Pharm"},{"key":"1996_CR33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.325","volume":"23","author":"JC Kalvass","year":"2002","unstructured":"Kalvass JC, Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327\u2013338","journal-title":"Biopharm Drug Dispos"},{"key":"1996_CR34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0006-8993(00)02758-X","volume":"879","author":"T Kageyama","year":"2000","unstructured":"Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, Hashida M, Kanai Y, Naito M, Tsuruo T, Minato N, Shimohama S (2000) The 4F2hc\/LAT1 complex transports l-DOPA across the blood\u2013brain barrier. Brain Res 879:115\u2013121","journal-title":"Brain Res"},{"key":"1996_CR35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/dmd.106.012369","volume":"35","author":"Q Wang","year":"2007","unstructured":"Wang Q, Morris ME (2007) Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos 35:201\u2013208","journal-title":"Drug Metab Dispos"},{"key":"1996_CR36","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1021\/jm701175d","volume":"51","author":"M Gynther","year":"2008","unstructured":"Gynther M, Laine K, Ropponen J, Leppanen J, Mannila A, Nevalainen T, Savolainen J, Jarvinen T, Rautio J (2008) Large neutral amino acid transporter enables brain drug delivery via prodrugs. J Med Chem 51:932\u2013936","journal-title":"J Med Chem"},{"key":"1996_CR37","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1002\/cmdc.201402281","volume":"9","author":"H Ylikangas","year":"2014","unstructured":"Ylikangas H, Malmioja K, Peura L, Gynther M, Nwachukwu EO, Leppanen J, Laine K, Rautio J, Lahtela-Kakkonen M, Huttunen KM, Poso A (2014) Quantitative insight into the design of compounds recognized by the l-type amino acid transporter 1 (LAT1). ChemMedChem 9:2699\u20132707","journal-title":"ChemMedChem"},{"key":"1996_CR38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bbamem.2004.05.008","volume":"1664","author":"DB Shennan","year":"2004","unstructured":"Shennan, DB, Thomson, J, Gow, IF, Travers, MT, Barber, MC (2004) l-leucine transport in human breast cancer cells (MCF-7 and MDA-MB-231): kinetics, regulation by estrogen and molecular identity of the transporter. Biochim Biophys Acta 1664:206\u2013216","journal-title":"Biochim Biophys Acta"},{"key":"1996_CR39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2133\/dmpk.21.173","volume":"21","author":"T Imai","year":"2006","unstructured":"Imai T (2006) Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 21:173\u2013185","journal-title":"Drug Metab Pharmacokinet"},{"key":"1996_CR40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/glia.21116","volume":"59","author":"D Braun","year":"2011","unstructured":"Braun D, Kinne A, Brauer AU, Sapin R, Klein MO, Kohrle J, Wirth EK, Schweizer U (2011) Developmental and cell type-specific expression of thyroid hormone transporters in the mouse brain and in primary brain cells. Glia 59:463\u2013471","journal-title":"Glia"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-016-1996-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-016-1996-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-016-1996-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T01:00:31Z","timestamp":1748998831000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-016-1996-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,14]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["1996"],"URL":"https:\/\/doi.org\/10.1007\/s11064-016-1996-8","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,14]]}}}